Top Markets
#1 Black Phoenix Black Phoenix +356.40%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +59.85%
#4 Gold Park Gold Park +56.34%
#5 Acurast Acurast +37.87%
#6 BasedHype BasedHype +26.41%
#7 OpenEden OpenEden +24.88%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.34%
#9 Cryptopia Cryptopia +21.54%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +15.54%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Clarus Therapeutics Holdings, Inc. Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc.

CRXTQ
Classifica tra le azioni #40846
Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to... Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism. The company has also entered into licensing agreements, including one with HavaH Therapeutics for androgen treatments targeting inflammatory breast disease and specific types of breast cancer. Additionally, Clarus holds an agreement with The Royal Institution for the Advancement of Learning/McGill University to advance and commercialize McGill's exclusive technology, which is designed to address human conditions associated with CoQ10 deficiencies. Founded in 2003, Clarus Therapeutics Holdings, Inc. is headquartered in Northbrook, Illinois. On September 5, 2022, the company, along with an affiliate, voluntarily sought reorganization under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.
Prezzo delle azioni
$0.0014
Ultima sincronizzazione: 2023-02-28
Capitalizzazione di mercato
$72.83K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Clarus Therapeutics Holdings, Inc. (CRXTQ)

Categoria

Healthcare
EPS per Clarus Therapeutics Holdings, Inc. (CRXTQ)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Clarus Therapeutics Holdings, Inc., l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per Clarus Therapeutics Holdings, Inc. da 2026 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
Non abbastanza dati per le date fornite.
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 $29.85 -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 $8.65 -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 $3.55 -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 $20.39 -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 $1.26 -
US